Page last updated: 2024-09-04

vatalanib and thalidomide

vatalanib has been researched along with thalidomide in 6 studies

Compound Research Comparison

Studies
(vatalanib)
Trials
(vatalanib)
Recent Studies (post-2010)
(vatalanib)
Studies
(thalidomide)
Trials
(thalidomide)
Recent Studies (post-2010) (thalidomide)
27642989,7891,3854,342

Protein Interaction Comparison

ProteinTaxonomyvatalanib (IC50)thalidomide (IC50)
Cereblon isoform 4Magnetospirillum gryphiswaldense7.8
Prostaglandin G/H synthase 1Ovis aries (sheep)0.37
Prostaglandin G/H synthase 2Ovis aries (sheep)0.5
DNA damage-binding protein 1Homo sapiens (human)1.38
Protein cereblonHomo sapiens (human)1.38

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Anderson, KC; Hayashi, T; Hideshima, T1
Kiziltepe, T; Sasisekharan, R; Sengupta, S1
Collins, TS; Hurwitz, HI1
Bockman, J; Rice, MC1
Anderson, KC; Podar, K1

Reviews

3 review(s) available for vatalanib and thalidomide

ArticleYear
Novel therapies for multiple myeloma.
    British journal of haematology, 2003, Volume: 120, Issue:1

    Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Enzyme Inhibitors; Estradiol; Heterocyclic Compounds, 3-Ring; Humans; Multiple Myeloma; NF-kappa B; Oxides; Phthalazines; Protease Inhibitors; Protein-Tyrosine Kinases; Pyridines; Thalidomide

2003
Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
    Seminars in oncology, 2005, Volume: 32, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Celecoxib; Colorectal Neoplasms; Humans; Neovascularization, Pathologic; Phthalazines; Pyrazoles; Pyridines; RNA, Catalytic; Sulfonamides; Thalidomide; Vascular Endothelial Growth Factors

2005
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
    Current cancer drug targets, 2011, Volume: 11, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway

2011

Other Studies

3 other study(ies) available for vatalanib and thalidomide

ArticleYear
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
A dual-color fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2004, Volume: 18, Issue:13

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bibenzyls; Cell Line, Tumor; Coculture Techniques; Doxorubicin; Extracellular Matrix; Fluorescence; Hepatocyte Growth Factor; Humans; Melanoma; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Stilbenes; Thalidomide; Vascular Endothelial Growth Factor A

2004
Anticancer Drug Discovery and Development - SRI's Seventh Annual Summit.
    IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:10

    Topics: Angiogenesis Inhibitors; Benzamides; Chemistry, Pharmaceutical; Clinical Trials as Topic; Cooperative Behavior; Diphenylamine; Drug Industry; Drugs, Investigational; Humans; Lenalidomide; Marketing; Phthalazines; Piperazines; Protein Serine-Threonine Kinases; Pyrazoles; Pyridines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Stem Cell Factor; Thalidomide; Thiophenes; Vascular Endothelial Growth Factor A

2005